BD与TD方案对老年多发性骨髓瘤患者的疗效比较

吴蕾; 王春芳; 熊健; 万坤; 赵娜; 冯广加

BD与TD方案对老年多发性骨髓瘤患者的疗效比较

- 复旦大学附属浦东医院上海浦东医院血液肿瘤科(上海, 201300)

详细信息

通讯作者: 熊健,E-mail:ciafbikgb004@163.com

中图分类号: R733.3

收稿日期: 2012-04-03

The curative effect of BD regimen in old multiple myeloma patient versus TD regimen

- Department of Hematology, Pudong Hospital, Fudan University, Shanghai, 201300, China

More Information

Corresponding author: XIONG Jian, E-mail: ciafbikgb004@163.com

Received Date: 03 April 2012

摘要

摘要: 目的：对比硼替佐米联合地塞米松（BD）方案和沙利度胺联合地塞米松（TD）方案对老年多发性骨髓瘤患者的疗效及不良反应。方法：回顾性分析24例老年多发性骨髓瘤病例，随机分为BD组和TD组，统计分析2组的缓解率及生存时间。结果：4个疗程后，BD组完全缓解（CR）4例，部分缓解（PR）6例，TD组完全缓解2例，部分缓解4例。BD组2年存活9例，4年存活5例，TD组2年存活6例，4年存活3例。BD组缓解率，生存期优于TD组。结论：BD方案较TD方案更适于老年多发性骨髓瘤患者的化疗。
- 多发性骨髓瘤 /
- 老年 /
- 硼替佐米 /
- 沙利度胺
Abstract: Objective: To compare the curative effect and side-effects of BD regimen in old multiple myeloma(MM) patients with TD regimen.Method: Data from 24 old multiple myeloma patients wer retrospectively analyzed who were divided into BD group and TD group.The remission rate and survival time were compared between two groups.Result: After four courses of treatment, four cases acquired CR and six cases acquired PR in BD regimengroup while in TD regimen group, two cases got CR and four cases got PR.2-years after treatment, nine cases survived in BD group and six survived in TD group.4 years after treatmen, five cases survived in BD group and three survived in TD group.The remission rate and survival time in BD groupare better than those in TD group.Conclusion: BD regimen is more suitable than TD regimen for old multiple myeloma patients.
- multiple myeloma /
- old /
- bortezomib /
- thalidomide

HTML全文

参考文献(10)

[1]	DURIE B, HAROUSSEAU J, MIGUEL J S.International uniform response criteria for multiple myeloma[J].Leukemia, 2006, 20:1467-1473.
[2]	SINGHAL S, MEHTA J, DESIKAN R.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med, 1999, 341:1565-1571.
[3]	MIKHAEL J, SCHUSTER S, JIMENEZ Z.Cyclophosphamide-bortezomib-dexamethasone (CYBORD) produces rapid and complete hematological response in patients with AL amyloidosis[J].Blood, 2012, 2:1182-1185.
[4]	BERENSON J, YANG H, SADLER K.Phase Ⅰ/Ⅱ trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J].J Clin Oncol, 2006, 24:937-944.
[5]	MITSUTOSHI S, RIEKO O, CHIGUSA Y.Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide[J].J Pharm Pharmaceut Sci, 2011, 14:78-89.
[6]	MAHMOUD R, JACOB P, ROBERT L.Management of myeloma-associated renal dysfunction in the era of novel therapies[J].Hematol, 2012, 5:51-68.
[7]	RICHARDSON P, SONNEVELD P, SCHUSTER M.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J].N Engl J Med, 2005, 352:2487-2498.
[8]	肖萌, 何娟, 李艳.BD方案与VAD方案治疗多发性骨髓瘤的疗效比较[J].中国医科大学学报, 2011, 40(4):352-356.
[9]	MORGAN G J, GREGORY W M, DAVIES F E, et al.The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J].Blood, 2012, 119:7-15.
[10]	ARGYRIOU A, ICONOMOU G, KALOFONOS H.Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature[J].Blood, 2008, 112:1593-1599.